ChiCTR-TRC-10001136
正在进行
/
/
/
2010-12-21
/
/
Childhood obstructive sleep apnoea
手術治療對輕度阻塞性睡眠呼吸暫停綜合症兒童的認知功能之影響
手術治療對輕度阻塞性睡眠呼吸暫停綜合症兒童的認知功能之影響\
Effect of adenotonsillectomy on behavioural problems in children with mild obstructive sleep apnoea
随机平行对照
其它
Computer-generated code
Single-blind
Departmental Fund
/
100
/
2010-12-28
1990-01-01
/
(i) Hong Kong Chinese prepubertal children aged between 6-11 years; (ii) Mild OSA confirmed by nocturnal PSG (obstructive apnoea hypopnoea index (OAHI) between 1 and 5) and parental report of habitual snoring (at least 3 nights per week); (iii) Tonsil size grading >=1; (iv) Written informed consent obtained from parents.；
请登录查看(i) Previous upper airway surgery. (ii) Diagnosed to have attention deficit hyperactivity disorder (ADHD) or other psychiatric behavioural problems. (iii) Craniofacial anomalies. (iv) Severe health problems that could be exacerbated by delayed treatment of OSA. (v) SpO2 nadir <90% in nocturnal PSG. (vi) Receiving any forms of treatment for OSA. (vii) Receiving any medications for allergic rhinitis including nasal corticosteroids and antihistamines within 6 weeks from baseline PSG. (viii) Parental report that child has reached menarche (female participants). (ix) Refusal of the surgical procedures. (x) Obese children, defined as having a BMI of >=95th percentile (corresponding to a z score of 1.645) of the local reference.；
请登录查看香港中文大學醫學院兒科學系
/
香港中文大學醫學院兒科學系的其他临床试验
香港中文大學醫學院兒科學系的其他临床试验
最新临床资讯
-
诺华：CFB抑制剂终止狼疮肾炎二期临床
医药笔记2026-10-17
-
泽安生物医药：实体瘤MCE启动一期临床
医药笔记2026-10-17
-
药明康德2026-10-17
-
沃森生物2026-10-16
-
罕见病信息网2026-10-16
-
武警特色医学中心2026-10-16
-
生物经纬2026-10-16
-
良医汇肿瘤资讯2026-10-16
-
BioMed科技2026-10-16
-
蒲公英资讯2026-10-16
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-10-26
-
2026-10-25
-
2026-10-25
-
摩熵咨询 33 49
-
摩熵咨询 20 3
-
摩熵咨询 20 10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
-
颁布机构：国家药品监督管理局药品审评中心 2026-09-28
-
颁布机构：国家药品监督管理局 2026-09-10
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-10-23
-
2026-10-23
-
2026-10-21
-
摩熵咨询 35 83
-
摩熵咨询 28 70
-
摩熵咨询 34 47
-
颁布机构：国家药品监督管理局 2026-10-19
-
颁布机构：国家市场监督管理总局 2026-10-16
-
颁布机构：国家市场监督管理总局 2026-09-30